Medicare GLP-1 Bridge program: What prescribers need to know
Effective July 1, 2026, CMS launched the Medicare GLP-1 Bridge program, a demonstration program that expands access to select GLP-1 medications (Foundayo, Wegovy, Zepbound KwikPen) specifically for weight management outside of Medicare Part D coverage. Prescribers must include obesity diagnosis codes (E66 family) and annotate prescriptions with 'Send to bridge for weight management' to route claims correctly; prior authorization is required and triggered automatically after the initial claim denial.